News, numbers of neuroscience

Written byAlla Katsnelson

| 2 min read

The third annual Neurotech Industry meeting in Boston kicked off yesterday morning (May 8) with some big numbers: * Two billion people each year are affected by brain-related illnesses, from stroke to depression to chronic pain, with an economic loss worldwide of about $2 trillion. * Venture capital companies invested about $1.77 billion in neuroscience-related research last year. * Worldwide, neuro-related industry profits hit $130.5 billion in 2007-- a growth of 8% from the previous year. The numbers come from the linkurl:Neurotech Industry Organization,;http://www.neurotechindustry.org/ a group formed about two years ago by a San Francisco entrepreneur named Zach Lynch, whose mission is to bring together academic researchers, companies, investors and patient advocacy groups "to give the brain a voice." The voice is also going to the legislature -- earlier this week, the NIO announced the introduction of a linkurl:a bill;http://www.the-scientist.com/article/display/12172/ in both houses of Congress to fund a national neurotechnology initiative. A total of $200 million would be split between the NIH, the FDA, and small business initiatives such as linkurl:SBIR;http://www.the-scientist.com/blog/display/54608/. Despite the statistics, the energy, and a burst of new ideas for potential treatments, a recurring theme at the meeting has been that developing treatments for brain diseases is hard row to hoe. Jay Watkins, managing director of De Novo Ventures, summed it up in a panel by recalling a comment he once made to his wife. "I've made an investment," he told her, "but you should probably think of it as a donation to Alzheimer's research." The company he was working with then, Eunoe, was developing an Alzheimer's therapy -- a shunt to drain protein tangles from the brain. Indeed, 10 years and just under $70 million later, the approach tanked. Neuro-related treatments have a linkurl:much higher failure rate;http://www.the-scientist.com/2007/10/1/36/1/ in clinical trials than other kinds of therapies. In part, that's because the placebo response in conditions such as depression and chronic pain is enormous -- some estimates have it at greater than 50%. Another problem specific to neurological treatments is what's called "soft endpoints" at the FDA. Assessments for conditions like depression and schizophrenia, and even Alzheimer's and epilepsy, are subjective -- using the same scale for depression, for example, one researcher might rank a patient differently than another. So it's much tougher to determine whether a therapy works. At lunch, I found myself sitting next to Paul Gilbert, the CEO of a company called Medavante that's working on a solution: Whether it's pain or depression or cognitive decline associated with Alzheimer's, take away local sites' financial incentives to enroll borderline patients (linkurl:clinical trial sites;http://www.the-scientist.com/2008/2/1/38/1/ can get as much as $10,000 for every patient they enroll) and standardize how the patients are assessed. Medavante is doing that using video conferencing and a trained team of 70 experts to do the assessment. It took about four years to convince pharma to try it, but with very first client, Bristol-Myers Squibb, the approach uncovered a significant effect in a potential drug that had shown no effect before. "They were just going to put it back on the shelf," Gilbert said.

News, numbers of neuroscience

The Scientist ARCHIVES

Become a Member of

Meet the Author

Alla Katsnelson

Related Research Resources

A Stubborn Gene, a Failed Experiment, and a New Path

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies